Full Press Release Details
Organigram Receives Health
Canada Approval for an Additional 17 Cultivation Rooms in Phase 4A
Additional licensed cultivation space brings annual
target production capacity to 61,000 kg/yr1
MONCTON, NB, June 24, 2019 Organigram Holdings Inc. (TSX
VENTURE: OGI) (NASDAQ: OGI), the parent company of Organigram Inc. (the
Company or Organigram ), a leading licensed producer of cannabis, is pleased
to announce that it has received approval from Health Canada for the licensing
of 17 additional cultivation rooms within the Phase 4A/4B perimeter of the
building. Thirteen of 31 Phase 4A cultivation rooms originally contemplated have
previously been licensed. The 31st room initially contemplated for
Phase 4A is being moved from the Company s 4A plans to its 4B licensing plans
thereby adjusting Phase 4A from 31 to 30 rooms and Phase 4B from 32 rooms to 33
The approval of the new cultivation rooms represents 14,000
kg/yr of increased target production capacity for total licensed production
capacity of 61,000 kg/yr (down from 62,000 kg/yr as a result of the room moved
from Phase 4A to 4B). This change was made to optimize licensing and
construction scheduling and continuity.
Sustainable growth, exceptional quality and constant
innovation are the pillars of our overall strategic approach, explains Greg
Engel, CEO, Organigram. We are proud to continue to increase our physical
capacity to meet the needs of cannabis consumers across the country while also
bringing new thinking and technology to our production. As a result of this
approval, cannabis plants will be moved into these new cultivation rooms on a
rolling basis commencing immediately. The Company anticipates being able to
begin to harvest product from these newly onboarded rooms by the end of
September, based on its historical cultivation timelines with the ability to
ship dried flower as early as mid-fall of 2019.
Subsequent Health Canada licensing amendment submissions will
follow expecting to allow for a continuous approval cycle of the remaining 33
Phase 4B cultivation rooms, mirroring the successful approach used with the
Company s Phase 2, 3 and 4A expansions.
The full Phase 4 expansion represents an aggregate of 77,000 kg
of additional annual capacity and is being completed in a series of stages (4A:
25,000 kg; 4B: 28,000 kg; and 4C: 24,000 kg) with final construction expected to
be completed by the end of calendar 2019. Once fully licensed and operational,
the expansion is expected to bring the Company s annualized target production
capacity to approximately 113,000 kg of dried flower equivalents.
Organigram s continued expansion reflects ongoing growth in
the cannabis marketplace, including increasing demand as new retail stores come
online in Alberta, Ontario, Quebec and British Columbia, explains Engel. The
expansion of our facility and production capacity will help ensure we have
additional product for extraction for the launch of the edibles and derivatives
market before the end of 2019. As previously disclosed, a Phase 5 refurbishment
is also underway for an edibles and derivative facility and additional in-house
extraction capacity.
____________________________________
forward-looking estimates of additional production capacity are based on a
number of material factors and assumptions. Please see the Company s most recent
MD&A available on SEDAR at www.sedar.com and the disclaimer at the end of
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select and TSX
Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc.,
is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing high-quality, indoor-grown
cannabis for patients and adult recreational consumers in Canada, as well as
developing international business partnerships to extend the Company's global
footprint. Organigram has also developed a portfolio of legal adult use
recreational cannabis brands including The Edison Cannabis Company, Ankr
Organics, Trailer Park Buds and Trailblazer. Organigram's primary facility is
located in Moncton, New Brunswick and the Company is regulated by the Cannabis
Act and the Cannabis Regulations (Canada).
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. This news
release contains forward-looking information. Often, but not always,
forward-looking information can be identified by the use of words such as
plans , expects , estimates , intends , anticipates , believes or
variations of such words and phrases or state that certain actions, events, or
results may , could , would , might or will be taken, occur or be
achieved. Forward-looking information involves known and unknown risks,
uncertainties and other factors that may cause actual results, events,
performance or achievements of Organigram to differ materially from current
expectations or future results, performance or achievements expressed or implied
by the forward-looking information contained in this news release. Examples of
such statements include statements with respect to target production capacity,
timing for submission of amendments and receipt of any required regulatory
approvals, timing for introduction of plants into rooms, cultivation and product
shipments. Risks, uncertainties and other factors involved with forward-looking
information could cause actual events, results, performance, prospects and
opportunities to differ materially from those expressed or implied by such
forward-looking information include unforeseen delays and any change in
conditions and is based on the assumptions that the facility size of the Moncton
Campus will be as estimated with the same amount of cultivation space being used
per cultivation room for cultivation as in prior phases; the ratio of dried
flower cultivated per canopy square foot of cultivation room will be consistent
with historical output in the Company s existing facilities; all cultivation
rooms designated as production rooms will be utilized for their intended
purposes; and construction of the facilities will be on time in accordance with
the estimates set out above and ready for final inspection by Health Canada in
time to meet the target onboarding dates; including risks as disclosed in the
Company s most recent annual information form, management s discussion and
analysis and other Company documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Although the Company believes that the assumptions and factors used in
preparing the forward-looking information in this news release are reasonable,
undue reliance should not be placed on such information and no assurance can be
given that such events will occur in the disclosed time frames or at all. The
forward-looking information included in this news release are made as of the